As a leading service provider in the field of cancer immunotherapy, Creative Biolabs now presents one-stop CAR-T therapy development service which has become a more promising therapeutic method to treat malignance. However, excessive activation of engineered CAR-T may cause severe toxicities such as cytokine storm. We offer a high-throughput platform to screen the potential small molecule drugs which can relief cytokine storm.
In modern therapeutics, CAR-T therapy shows a promising activity for cancer treatment. While, CAR-T therapy does not exist alone as CAR-T can lead to excessive T cell expansion in vivo, and in turn trigger release of toxic levels of cytokines. It’s also known as cytokine storm or cytokine release syndrome (CRS) ranging from mild swelling, nausea, and fever, to life-threatening multi-organ failure, even death. Hence, to prevent or limit the cytokine toxicities, CAR-T therapy must need to be combined with other approaches to achieve a better treatment outcome. One of the promising strategies is to utilize small inhibitory molecules to suppress the cytokine release. Creative Biolabs now provides our clients with advanced high-throughput screening assay to investigate the potential candidates.
Introduction of Small Molecule Drug Discovery Assay for Cytokine Storm Inhibition
Once the immune system is activated by CAR-T cell with high specificity to recognize tumor antigen, CRS can be induced with consecutive release of cytokines such as interferon gamma (IFN-γ) or tumor necrosis factor alpha (TNF-α) via T cell activation, target cell lysis, and further innate immune cell activation. To enhance the safety of CAR-T therapy and suppress CRS side effect, strategies to overcome the toxicities are proposed including small molecules with the capability of cytokine release inhibition. This assay consists of clients’ interested small molecules, CAR-T cells, tumor cells, and cytokine release assays. Solution, wet and dry coating presentations of small molecules are available. Typical tested cytokines are IFN-γ, TNF-α, IL-1β, IL-2, IL-8, IL-10 and IL-12p70. Other cytokine markers can also be tested upon specific requirements of our clients. For cytokine release detection, multiplexed assays are available including enzyme-linked immunospot assay (ELISpot), intracellular cytokine staining assay (ICS), and flow cytometry. Our senior scientists will help provide the most suitable assay for clients to test the investigational small molecules.
Fig. 1 Diagram of small molecules reduce cytokine production
Highlight Features of Our Service
With capabilities of various cytokine release assays, multiple analysis technologies and instruments, Creative Biolabs has established a powerful advanced platform which can be used to test your investigational small molecules against CAR-T and tumor cells through cytokine release assays. We are committed to offering this high-throughput screening assay to facilitate the small molecule discovery. Please don’t hesitate to let us know your demands, and our team will get back to you as soon as we can.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE